Point72 Asset Management L.P. bought a new position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 51,900 shares of the company’s stock, valued at approximately $2,522,000. Point72 Asset Management L.P. owned approximately 0.14% of Aerie Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alyeska Investment Group L.P. lifted its position in shares of Aerie Pharmaceuticals by 218.8% during the third quarter. Alyeska Investment Group L.P. now owns 191,282 shares of the company’s stock worth $9,296,000 after purchasing an additional 131,282 shares in the last quarter. Stifel Financial Corp raised its holdings in Aerie Pharmaceuticals by 2.0% in the third quarter. Stifel Financial Corp now owns 84,837 shares of the company’s stock valued at $4,117,000 after acquiring an additional 1,655 shares in the last quarter. OxFORD Asset Management LLP acquired a new stake in Aerie Pharmaceuticals in the third quarter valued at $859,000. Moody Aldrich Partners LLC acquired a new stake in Aerie Pharmaceuticals in the third quarter valued at $1,046,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in Aerie Pharmaceuticals by 10.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 152,668 shares of the company’s stock valued at $7,420,000 after acquiring an additional 14,379 shares in the last quarter.

Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) opened at $57.25 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 15.24 and a quick ratio of 15.24. Aerie Pharmaceuticals Inc has a 12 month low of $35.50 and a 12 month high of $66.60.

AERI has been the topic of several recent analyst reports. Guggenheim initiated coverage on shares of Aerie Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $80.00 price target on the stock. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Mizuho reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a report on Friday, November 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $62.00 price target on shares of Aerie Pharmaceuticals in a report on Wednesday, October 11th. Finally, Cowen reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a report on Thursday, October 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $72.00.

ILLEGAL ACTIVITY WARNING: “Point72 Asset Management L.P. Buys New Stake in Aerie Pharmaceuticals Inc (AERI)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/21/point72-asset-management-l-p-buys-new-stake-in-aerie-pharmaceuticals-inc-aeri.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.